Literature DB >> 24974908

iPSC-derived human mesenchymal stem cells improve myocardial strain of infarcted myocardium.

Qingfeng Miao1, Winston Shim, Nicole Tee, Sze Yun Lim, Ying Ying Chung, K P Myu Mia Ja, Ting Huay Ooi, Grace Tan, Geraldine Kong, Heming Wei, Chong Hee Lim, Yoong Kong Sin, Philip Wong.   

Abstract

We investigated global and regional effects of myocardial transplantation of human induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (iMSCs) in infarcted myocardium. Acute myocardial infarction (MI) was induced by ligation of left coronary artery of severe combined immunodeficient mice before 2 × 10(5) iMSCs or cell-free saline were injected into peri-infarcted anterior free wall. Sham-operated animals received no injection. Global and regional myocardial function was assessed serially at 1-week and 8-week by segmental strain analysis by using two dimensional (2D) speckle tracking echocardiography. Early myocardial remodelling was observed at 1-week and persisted to 8-week with global contractility of ejection fraction and fractional area change in saline- (32.96 ± 14.23%; 21.50 ± 10.07%) and iMSC-injected (32.95 ± 10.31%; 21.00 ± 7.11%) groups significantly depressed as compared to sham control (51.17 ± 11.69%, P < 0.05; 34.86 ± 9.82%, P < 0.05). However, myocardial dilatation was observed in saline-injected animals (4.40 ± 0.62 mm, P < 0.05), but not iMSCs (4.29 ± 0.57 mm), when compared to sham control (3.74 ± 0.32 mm). Furthermore, strain analysis showed significant improved basal anterior wall strain (28.86 ± 8.16%, P < 0.05) in the iMSC group, but not saline-injected (15.81 ± 13.92%), when compared to sham control (22.18 ± 4.13%). This was corroborated by multi-segments deterioration of radial strain only in saline-injected (21.50 ± 5.31%, P < 0.05), but not iMSC (25.67 ± 12.53%), when compared to sham control (34.88 ± 5.77%). Improvements of the myocardial strain coincided with the presence of interconnecting telocytes in interstitial space of the infarcted anterior segment of the heart. Our results show that localized injection of iMSCs alleviates ventricular remodelling, sustains global and regional myocardial strain by paracrine-driven effect on neoangiogenesis and myocardial deformation/compliance via parenchymal and interstitial cell interactions in the infarcted myocardium.
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

Entities:  

Keywords:  cell therapy; myocardial compliance; myocardial strain; telocytes; tissue deformation

Mesh:

Year:  2014        PMID: 24974908      PMCID: PMC4190910          DOI: 10.1111/jcmm.12351

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


Introduction

Clinical evaluation of bone marrow-derived mesenchymal stem cells (BM-MSCs) in regenerative cardiac repair after myocardial infarction (MI) has been widely reported [1-3]. Despite early optimism in cellular replacement therapy, beneficial effects of BM-MSCs have largely been attributed to secreted paracrine factors that enhanced angiogenesis and modulated positive ventricular remodelling [4]. On the other hand, the seminal work of Popescu and colleagues has revealed telocyte as a distinct interstitial cell from fibroblasts [5] and other stromal cells [6]. Their close association with cardiac progenitors [7] and neoangiogenic endothelial cells [8] has increasingly been recognized to confer beneficial effects on human heart [9-11] that may have important implications in cardiac repair. Compared to conventional BM-MSCs, alternative MSCs with superior proliferative potential and regenerative function have recently been derived from pluripotent stem cells such as human embryonic stem cells (ESC) [12] and induced pluripotent stem cells (iPSCs) by our group [13]. The ESC-derived MSCs have been reported to repair infarcted myocardium via paracrine effect comparable to adult-derived MSCs [14]. Moreover, angiogenic cytokines secreted from ESC-derived MSCs has also been reported as the main contributor in reducing ischaemia/reperfusion injury in a porcine model [15]. Bone marrow-derived MSCs are known improve global cardiac performance in dysfunctional myocardium majorly by ameliorating negative myocardial remodelling via restricting ventricular dilatation and enhancing neoangiogenesis [16]. Furthermore, BM-MSCs have been suggested to benefit cardiac performance by modulating tissue compliance and stress/strain response of infarcted myocardium [17]. Similarly, myocardial telocytes have been implicated in the repair of infarcted myocardium by recovering inter-cellular interactions via re-establishing connectivity and enhancing angiogenesis that benefited the restructuring infarct milieu [18]. Utilization of speckle tracking echocardiography (STE) in demonstrating myocardial strain may be helpful in delineating such re-established myocardial connectivity locally as STE affords regional quantification of structural deformational response of myocardial tissue in a multi-dimensional axis of radial, longitudinal and circumferential contractility that may be more informative in functional assessment after cardiac therapy [19]. It is unclear how localized transplantation of MSCs in a regional infarcted wall of left ventricle contribute to myocardial strain associated tissue deformation [20,21] and if telocytes have any role in myocardial compliance following MI. In this study, we investigated the global and regional myocardial strain of iPSC-derived MSCs (iMSCs) transplanted myocardium and associated myocardial telocytes by 2D strain analysis using STE.

Materials and methods

Generation and characterization of iPSC-derived MSCs

The iPSC cell line utilized for derivation of mesenchymal stem cells (iMSCs) was generated from neonatal human dermal fibroblasts as described previously [13]. Briefly, to isolate the iMSCs, iPSCs were differentiated via embryoid bodies (EBs) and attached onto culture dish to enable outgrowth of cells. The cells were isolated and expanded in DMEM (Sigma-Aldrich, St. Louise, MO, USA) supplemented with 10% foetal bovine serum (Hyclone. Thermo Fisher Scientific Inc, Waltham, MA, USA) he expanded cells were shown to express ∼90% positive surface markers of CD29, CD44, CD73, CD90 and CD105, which are characteristic markers for MSC. The derived iMSCs expanded exponentially up to 20 passages, retained stable telomerase activity and demonstrated multipotent capacity via directed differentiation into adipocytes/oesteocytes/chondrocytes as described [13]. Early passage iMSCs (up to passage 10) were used for subsequent experiments.

Animal surgery and transplantation

The animal study was approved by the Singapore General Hospital IACUC committee and conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No.85-23, revised 1996). Healthy female mice with severe combined immune deficiency (SCID) (10–12 weeks of age, weight 20–25 g) were used. Mice were induced and intubated with 1.5–2% isoflurane while connected to a small animal ventilator (model 687; Harvard Apparatus, Holliston, MA, USA) with a stroke volume (SV) of 0.3–0.5 ml/min. and respiration rate of 120 beats/min. All surgical manipulations were performed under a Leica stereotactic operation microscope on a heated surgical pad (Harvard Apparatus) at 37°C. A left thoracotomy was performed in the fourth intercostal space to assess anterior wall of the heart and the left anterior coronary artery was identified distal to the level of left atrium followed by passing a 7-0 suture (Ethicon, Johnson and Johnson, New Brunswick, NJ, USA) underneath the artery. The animals (n = 24) were randomly divided into three groups: sham-operated animals with mock infarction without ligating the suture over left coronary artery, saline-injected animals that received serum-free DMEM media (50 μl) or iMSC-injected animals that received 2 × 105 cells in serum-free media (50 μl) intramyocardially into the LV free wall bordering the infarct zone via a 29G needle at approximately 45° canted angle, after the left coronary artery was permanently ligated. Immediately following ligation, occlusion was confirmed by observation of the LV pallor. The animal was gradually weaned off the ventilator until fully recovered and had free access to standard chow and water until next follow-up.

Echocardiography and 2D speckle tracking analysis

Echocardiography was performed at baseline, 1-week and 8-week after infarction on Vevo2100 (VisualSonics VSI, Toronto, ON, Canada) with MS400 linear array transducer (38 MHz) by using optimized sector width for complete myocardial visualization (50 and 110 μm axial and lateral resolution respectively) and endocardial definition. A 2D guided M-mode of parasternal short axis at papillary muscle level was obtained to measure standard parameters. Long-axis view was used to obtain fractional area change (FAC = Simpson areaEd − Simpson areaES/Simpson areaEd), ventricular chamber volumes and left ventricular ejection fraction (LVEF) were derived by using a modified Quinones method [22]. Average of 10 cardiac cycles at each plane was stored in cineloop for subsequent offline analysis. Standard parasternal long axis and short axis at mid papillary muscle level views with frame rate more than 200 frames/sec. recommended for optimal speckle tracking analysis was used. Global peak radial (RS) and circumferential strain (CS) sampled from anterior, lateral, posterior, inferior, postero-septal and antero-septal segments were measured from the short-axis view. Global peak longitudinal strain (LS) was measured from anterior basal, mid, apical and posterior basal, mid, apical segments from long-axis view. Strain data were analysed by VevoStrain version 1.3.0 (VisualSonics VSI).

Histology and immunostaining

The harvested hearts were cryo-processed by using OCT Tissue-Tek medium. Hearts were sectioned transversely from the basal part to the apex of the left ventricle by using a cryostat with 5-um thickness (Leica AG, Solms, Germany). Masson's Trichrome staining (Sigma-Aldrich) was performed to quantify infarct size. The percentage infarct scar size was estimated from infarct area over total LV area by using a calibrated M205 steromicroscope (Leica AG). Overnight incubation with antibody against human-specific Ku80 (Clone EPR3468; Abcam, Cambridge, MA, USA) was used to identify the transplanted human iMSC and antibody against CD34 (clone 581; BD Biosciences, San Jose, CA, USA) was used to identify myocardial interstitial cells in the mouse heart and antibodies against α-actinin and α-smooth muscle actin (SMA) were used to identify cardiac muscle and vascular smooth muscle cells respectively (Sigma-Aldrich). Signals visualization was performed with 3,3′-diaminobenzidine (DAB) before counterstaining nuclei with haematoxylin and brightfield images analysed on a micrometre calibrated M200 microscope (Carl Zeiss, Gottingen, Germany). For vascular angiogenesis, microvessels of less than 200-μm caliber in the peri-infarcted myocardium, away from the pericardium, were identified by using antibody against von Willebrand factor (Dako, Glostrup, Denmark) and mature vessels were confirmed by co-staining by using antibody against α-SMA (Sigma-Aldrich) and Alexa Fluor488/555-conjugated secondary antibodies (Life Technologies, Carlsbad, CA, USA) before counterstaining the nuclei with 4′,6-diamidino-2-phenylindole (DAPI) and signals visualized by using M200 fluorescent microscope (Carl Zeiss). For co-staining of Ku80 identified human cells in histology sections (visualized by using DAB colorimetric method), sequential staining with primary antibody against CD34, α-actinin or α-SMA was followed by fluorescent secondary antibody.

Statistical analysis

Data were presented as mean ± SD. Global peak strain was calculated as the average of all measurable segments. anova was performed comparing among experimental groups followed by post hoc analysis by using Dunnett t-test for all comparisons while Tukey test was performed for segment by segment comparison of speckle strain and neovascularization analysis for normally distributed data. Analysis was performed with SPSS software (version 13, SPSS Inc, Chicago, IL, USA) with P < 0.05 considered statistically significant.

Results

Cardiac performance

The proliferative and multipotent property of the iMSCs have been previously characterized by our group where successive expansion rapidly yielded large quantities of iMSCs in culture while adult BM-MSCs lost such potency with rapid telomere shortening [13]. Those expanded iMSC retained spindle morphology and MSC characteristics throughout passages before myocardial transplantation into peri-infarct region of acutely infarcted SCID mice. There were no significant differences in all cardiac indices examined at 1-week afetr infarction among the sham-operated, saline-injected or iMSC-injected groups (Table 1). However, when compared to sham-operated control (3.74 ± 0.32 mm), transplantation of iMSC (4.24 ± 0.58 mm) into the peri-infarct region salvaged ventricular chamber geometry while saline-injection (4.40 ± 0.62 mm, P < 0.05) failed to restrict myocardial dilatation at 8-week after intervention. Furthermore, speckle tracking analysis of the regional wall in parasternal short-axis view (Fig. 1A) showed that iMSC (25.67 ± 12.53%) protected mean radial strain (six segments of anterior, lateral, posterior, inferior, posteroseptal and anteroseptal walls) of the left ventricle while functional deterioration was observed in saline-injected (21.50 ± 10.07%, P < 0.05) animals (Fig. 2, Table S1). This protected contractility was further corroborated by findings from the parasternal long-axis view (Fig. 1B) whereby iMSC transplanted animals (17.72 ± 4.86%) preserved ventricular radial strain, but not saline-injection (15.84 ± 7.24%, P < 0.05), when compared to sham-operated (24.95 ± 6.13%) animals (Fig. 2, Table S1). Nevertheless, neither iMSC (33.19 ± 10.99%, P < 0.05) nor saline-injection (32.96 ± 14.23%, P < 0.05) rescued the compromised LVEF and FAC when compared to sham-operated (51.17 ± 11.69%) animals (Table 1).
Table 1

Cardiac hemodynamics assessment by 2-D echocardiography

Baseline1-week8-week



2D EchoSham (n = 8)Saline (n = 8)iMSC (n = 8)Sham (n = 8)Saline (n = 8)iMSC (n = 8)Sham (n = 8)Saline (n = 8)iMSC (n = 8)
LVWTed (mm)0.73 ± 0.070.77 ± 0.110.72 ± 0.060.79 ± 0.180.89 ± 0.140.84 ± 0.120.84 ± 0.170.85 ± 0.190.76 ± 0.15
LVIDed (mm)3.54 ± 0.143.62 ± 0.233.35 ± 0.223.65 ± 0.363.95 ± 0.413.65 ± 0.363.74 ± 0.324.40 ± 0.62*4.24 ± 0.58
LVWTes (mm)1.05 ± 0.111.06 ± 0.161.04 ± 0.171.08 ± 0.201.22 ± 0.261.08 ± 0.201.12 ± 0.231.09 ± 0.311.05 ± 0.30
LVIDes (mm)2.36 ± 0.212.61 ± 0.332.18 ± 0.402.56 ± 0.502.67 ± 0.472.73 ± 0.462.62 ± 0.583.40 ± 0.713.25 ± 0.81
EDV (μl)45.43 ± 4.7447.93 ± 7.0545.22 ± 4.9753.57 ± 11.0064.40 ± 19.2358.15 ± 19.2657.28 ± 8.7281.33 ± 31.3476.24 ± 29.03
ESV (μl)21.59 ± 2.9125.66 ± 6.7721.19 ± 2.5329.59 ± 11.7543.12 ± 19.2840.27 ± 18.9927.97 ± 9.7557.68 ± 30.2253.41 ± 29.14
FS (%)35.33 ± 3.6727.94 ± 5.6635.34 ± 8.4230.37 ± 8.9532.67 ± 6.7025.41 ± 8.2730.62 ± 9.5523.31 ± 6.4424.36 ± 9.41
LVEF (%)52.41 ± 5.3347.38 ± 10.4652.89 ± 5.9445.91 ± 12.6735.78 ± 13.2833.46 ± 11.6551.17 ± 11.6932.96 ± 14.23*33.19 ± 10.99*
FAC (%)35.33 ± 3.6732.13 ± 7.6935.00 ± 4.8331.38 ± 9.3324.13 ± 8.6321.63 ± 7.9334.86 ± 9.8221.50 ± 10.07*21.25 ± 7.55*

P < 0.05 versus sham-operated control.

LVWTed/es: left ventricle wall thickening at end diastole/systole; LVIDed/es: left ventricle internal dimension at end diastole/systole; EDV: end diastolic volume; ESV: end systolic volume; FS: fractional shortening; LVEF: left ventricular ejection fraction; FAC: fractional area change.

Fig. 1

Short-axis and long-axis views of speckle tracking echocardiography. (A) Six-segment view from short axis of a mouse heart. (B) Six-segment view from long axis of a mouse heart. Ant.: anterior; post.: posterior; Inf.: inferior.

Fig. 2

Global peak strain analysis of LV systolic deformations at baseline and follow-up. SAX: short-axis view; LAX: long-axis view.

Cardiac hemodynamics assessment by 2-D echocardiography P < 0.05 versus sham-operated control. LVWTed/es: left ventricle wall thickening at end diastole/systole; LVIDed/es: left ventricle internal dimension at end diastole/systole; EDV: end diastolic volume; ESV: end systolic volume; FS: fractional shortening; LVEF: left ventricular ejection fraction; FAC: fractional area change. Short-axis and long-axis views of speckle tracking echocardiography. (A) Six-segment view from short axis of a mouse heart. (B) Six-segment view from long axis of a mouse heart. Ant.: anterior; post.: posterior; Inf.: inferior. Global peak strain analysis of LV systolic deformations at baseline and follow-up. SAX: short-axis view; LAX: long-axis view. Segmental short-axis speckle tracking analysis revealed that ventricular radial strain at the lateral, posterior, inferior and posteroseptal walls were significantly compromised in the saline-injected animals while only posterior wall strain remained depressed in the iMSC-injected animals at 8-week afetr MI (Table 2). The ligation infarcted anterior wall that received iMSC showed better radial strain, although there was no significant difference between the iMSC and saline-injected animals. Nevertheless, segmental long-axis speckle tracking analysis of radial strain revealed a significant improvement in the anterior basal segment that coincided with iMSC-injected territory (Table 3). Circumferential and longitudinal strain were minimally affected whereby only inferior (circumferential strain) wall (−17.22 ± 7.26% versus −24.41 ± 5.62%, P < 0.05) of saline-injected (Table 2) and posterior apical (longitudinal strain) wall (−10.58 4.96% versus −23.63 8.55%, P < 0.05) of iMSC-injected animals (Table 3) remained significantly difference than sham-operated control at 8-week after infarction.
Table 2

Segmental analysis of myocardial strain in short axis

8-week

Speckle tracking analysisSham (n = 8)Saline (n = 8)iMSC (n = 8)Stats sig.
Short-axis view (SAX)
Mean radial strain (RS; %)34.88 ± 5.7721.50 ± 5.31*25.67 ± 12.53P < 0.05
 Anterior wall27.46 ± 8.7120.53 ± 10.6526.60 ± 18.99NS
 Lateral wall35.96 ± 8.3519.33 ± 8.73*23.53 ± 23.51P < 0.05
 Posterior wall41.49 ± 8.9125.34 ± 9.84*23.26 ± 15.12*P < 0.05
 Inferior wall42.98 ± 11.5925.19 ± 14.39*28.62 ± 9.87P < 0.05
 Posterior septal wall32.12 ± 6.6120.44 ± 5.89*25.76 ± 10.09P < 0.05
 Anterior septal wall29.69 ± 9.0418.35 ± 6.0825.31 ± 11.64NS
Mean circumferential strain (CS; %)−22.82 ± 5.36−16.61 ± 4.74#−19.25 ± 5.64P = 0.051
 Anterior wall−16.23 ± 5.33−13.21 ± 5.18−15.65 ± 7.01NS
 Lateral wall−21.82 ± 9.15−16.73 ± 4.54−15.63 ± 8.86NS
 Posterior wall−21.32 ± 4.62−16.33 ± 6.54−16.53 ± 7.24NS
 Inferior wall−24.41 ± 5.62−17.22 ± 7.26*−22.12 ± 7.72P < 0.05
 Posterior septal wall−32.01 ± 7.50−21.12 ± 8.29−25.75 ± 5.55NS
 Anterior septal wall−19.94 ± 8.33−15.53 ± 10.33−18.18 ± 4.70NS
Table 3

Segmental analysis of myocardial strain in long-axis view

8-week

Speckle tracking analysisSham (n = 8)Saline (n = 8)iMSC (n = 8)Stats sig.
Long-axis view (LAX)
Mean radial strain (RS; %)24.95 ± 6.1315.84 ± 7.24*17.72 ± 4.86P < 0.05
 Posterior basal wall21.93 ± 3.8421.26 ± 14.8822.17 ± 12.37NS
 Posterior mid wall24.18 ± 8.1919.72 ± 12.8712.85 ± 10.57NS
 Posterior apical wall21.18 ± 7.9811.74 ± 9.7210.60 ± 5.38NS
 Anterior basal wall22.18 ± 4.1315.81 ± 9.8328.86 ± 8.16*P < 0.05
 Anterior mid wall27.35 ± 9.8115.18 ± 13.9220.14 ± 14.19NS
 Anterior apical wall29.55 ± 11.6112.92 ± 13.2214.78 ± 15.45NS
Mean longitudinal strain (LS; %)−15.74 ± 2.46−12.84 ± 4.83−13.08 ± 2.55NS
 Posterior basal wall−12.66 ± 5.11−18.53 ± 4.19−14.18 ± 6.72NS
 Posterior mid wall−16.59 ± 3.32−10.71 ± 5.99−11.71 ± 6.74NS
 Posterior apical wall−23.63 ± 8.55−13.00 ± 9.58−10.58 ± 4.96*P < 0.05
 Anterior basal wall−14.41 ± 5.14−18.02 ± 5.18−20.17 ± 6.03NS
 Anterior mid wall−10.05 ± 3.87−7.64 ± 4.32−12.15 ± 4.62NS
 Anterior apical wall−15.66 ± 6.48−11.44 ± 6.59−10.16 ± 5.20NS
Segmental analysis of myocardial strain in short axis Segmental analysis of myocardial strain in long-axis view

Localization of transplanted iMSC

In examining the cross section tissue histology of the injected heart (Fig. 3A), transplanted iMSC were found mostly localized within the injected anterior wall in the peri-infarcted zone (Fig. 3B and C) bordering the lateral wall as well as in the infarcted zone (Fig. 3D). The iMSC that stained positive for human-specific Ku80 nuclear marker (Fig. 3E–G) were scattered among host cardiac fibroblasts and myocardial interstitial cells within the actively remodelling regions of anterior epicardium and myocardium. Rare iMSC were occasionally found in the endocardium of anterior wall region and sparingly as isolated single cells in the lateral wall that borders the anterior wall. Expectedly, no Ku80 positive human cells were detected in the saline-injected or sham-operated heart (Fig. 3H and I). Consistent with their interstitial localization, the Ku80 positive transplanted iMSCs (Fig. 4A, B and E) did not show appreciable differentiation towards cardiomyocytes (Fig. 4C and D) or vascular smooth muscle or endothelial cells (Fig. 4G and H).
Fig. 3

Myocardial localization of transplanted human iMSC in the anterior segment of left ventricle. (A) Six-segment view of transverse sectioned mouse heart injected with iMSCs. (B) Human-specific nuclear staining of Ku80 in iMSCs in peri-infarcted zone of anterior segment bordering lateral wall. (C) Human-specific nuclear staining of Ku80 in iMSCs in peri-infarcted zone of anterior segment next to infarcted wall. (D) Identification of human Ku80 stained iMSCs in the infarcted zone of anterior wall. (E–G) Magnified views of boxed region in B, C and D. (H) Transverse sectioned view of saline-injected mouse heart. (J) Magnified view of infarct border in H. (I) Transverse sectioned view of sham-operated mouse heart. (K) Magnified view of injured border in I. Scale bar: 1 mm (A, H and I); 20 μm (for all others).

Fig. 4

Interstitial localization of transplanted human iMSCs in myocardium. (A) Presence of human-specific nuclear staining of Ku80 iMSCs in the interstitial space of cardiac muscle. (B–D) Magnified view of boxed region in A, showing Ku80 stained iMSCs located mainly in the interstitial space (demarcated line) of α-actinin (green) stained cardiac muscle. (E) Presence of human-specific nuclear staining of Ku80 iMSCs in fibrous/collagenous region of myocardium. (F–H) Magnified view of boxed region in E, showing Ku80 stained human iMSCs (arrows) located in peri-vascular space of α-smooth muscle actin (SMA) stained microvessels; scale bar: 50 μm.

Myocardial localization of transplanted human iMSC in the anterior segment of left ventricle. (A) Six-segment view of transverse sectioned mouse heart injected with iMSCs. (B) Human-specific nuclear staining of Ku80 in iMSCs in peri-infarcted zone of anterior segment bordering lateral wall. (C) Human-specific nuclear staining of Ku80 in iMSCs in peri-infarcted zone of anterior segment next to infarcted wall. (D) Identification of human Ku80 stained iMSCs in the infarcted zone of anterior wall. (E–G) Magnified views of boxed region in B, C and D. (H) Transverse sectioned view of saline-injected mouse heart. (J) Magnified view of infarct border in H. (I) Transverse sectioned view of sham-operated mouse heart. (K) Magnified view of injured border in I. Scale bar: 1 mm (A, H and I); 20 μm (for all others). Interstitial localization of transplanted human iMSCs in myocardium. (A) Presence of human-specific nuclear staining of Ku80 iMSCs in the interstitial space of cardiac muscle. (B–D) Magnified view of boxed region in A, showing Ku80 stained iMSCs located mainly in the interstitial space (demarcated line) of α-actinin (green) stained cardiac muscle. (E) Presence of human-specific nuclear staining of Ku80 iMSCs in fibrous/collagenous region of myocardium. (F–H) Magnified view of boxed region in E, showing Ku80 stained human iMSCs (arrows) located in peri-vascular space of α-smooth muscle actin (SMA) stained microvessels; scale bar: 50 μm. Coincided with the presence of human Ku80 positively identified iMSC in the injected anterior wall, CD34 stained interstitial cells (Fig. 5A) with long cellular processes that resembled telopodes (Fig. 5B) of reported myocardial telocytes [6,23] were found nestled intimately with other interstitial cells mostly in the collagen-rich extracellular environment within the infarcted zone (Fig. 5C). Furthermore, such CD34+ telocytes were positive for human-specific Ku80 antigen (Fig. 5D and E) and were found to intermingle with resident CD34+ myocardial telocytes that were negative for the human antigen (Fig. 5F and G). In comparison, such distinct staining for CD34+ telocytes was mostly absent in the interstitial environment of infarcted anterior wall of saline-injected or sham-operated animals (Fig. 5H and I).
Fig. 5

Presence of CD34 stained interstitial cells in the infarct zone. (A) Interstitial cells with long cellular processes that stained positive for CD34 that resided longitudinally in the collagen-rich and remodelling infarct zone of iMSC transplanted heart. (B and C) Magnified view of CD34 stained cells with thin and long cellular processes resembled podomers (arrows) and podom (arrowhead) of myocardial telocytes in the interstitial space. (D) Presence of human-specific nuclear staining of Ku80 iMSCs and interstitial cells in peri-infarct zone. (E–G) Magnified view of boxed region in D, showing Ku80 and CD34 double-stained human telocyte (arrow) in close proximity with CD34 stained (but human Ku80 negative) resident telocyte (*). (H) Absence of CD34 stained interstitial cells in the infarct zone of saline-injected mouse heart. (I) Absence of CD34 stained interstitial cells in the injured zone of sham-operated mouse heart. Dotted line demarcates intact myocardium from infarct zone. Scale bar: 50 μm (A, D–I); 10 μm (B and C).

Presence of CD34 stained interstitial cells in the infarct zone. (A) Interstitial cells with long cellular processes that stained positive for CD34 that resided longitudinally in the collagen-rich and remodelling infarct zone of iMSC transplanted heart. (B and C) Magnified view of CD34 stained cells with thin and long cellular processes resembled podomers (arrows) and podom (arrowhead) of myocardial telocytes in the interstitial space. (D) Presence of human-specific nuclear staining of Ku80 iMSCs and interstitial cells in peri-infarct zone. (E–G) Magnified view of boxed region in D, showing Ku80 and CD34 double-stained human telocyte (arrow) in close proximity with CD34 stained (but human Ku80 negative) resident telocyte (*). (H) Absence of CD34 stained interstitial cells in the infarct zone of saline-injected mouse heart. (I) Absence of CD34 stained interstitial cells in the injured zone of sham-operated mouse heart. Dotted line demarcates intact myocardium from infarct zone. Scale bar: 50 μm (A, D–I); 10 μm (B and C).

Infarct size and vascular density

In comparison to sham-operated animals (5.53 ± 3.91%) that showed mostly epicardial fibrotic response as a result of mock ligation-induced injury and no visible thinning of the anterior wall of the left ventricle (Fig. 6A), both iMSC-injected and saline-injected animals sustained larger transmural infarct and anterior wall thinning. Though smaller in severity, infarct size in animals that received iMSCs (14.08 ± 4.59%) was statistically insignificant when compared to saline-injected (17.36 ± 15.26%) animals (Fig. 6B).
Fig. 6

Infarct staining with Masson's trichrome staining. (A). Sham-operated mouse heart showing epicardial injury with limited fibrotic response and transmural anterior infarct with wall thinning and myocardial fibrosis in saline-injected and iMSC-injected mouse heart. (B) Quantitative estimation of infarct size at 8-week after infarction; scale bar: 1 mm.

Infarct staining with Masson's trichrome staining. (A). Sham-operated mouse heart showing epicardial injury with limited fibrotic response and transmural anterior infarct with wall thinning and myocardial fibrosis in saline-injected and iMSC-injected mouse heart. (B) Quantitative estimation of infarct size at 8-week after infarction; scale bar: 1 mm. Consistent with better regional contractility following iMSC transplantation, there was a significantly higher vascular density count in the iMSC-injected (271.25 ± 30.38 microvessels/mm2 myocardial tissue, P < 0.05) animals as compared to the saline-injected (176.29 ± 77.99 microvessels/mm2 myocardial tissue) and sham-operated (123.02 ± 48.84 microvessels/mm2 myocardial tissue) animals at 8-week after infarction (Fig. 7A and B). Furthermore, the newly formed microvessels in the iMSC-injected (24.92 ± 2.32 α-SMA+ vessels/mm2 myocardial tissue, P < 0.05), but not the saline-injected (18.53 ± 6.54 α-SMA+ vessels/mm2 myocardial tissue) animals, were significantly more matured microvasculature accompanied by α-SMA as compared to the sham-operated (18.12 ± 3.75 α-SMA+ vessels/mm2 myocardial tissue) animals (Fig. 7C).
Fig. 7

Microvascular neoangiogenesis at 8-week after myocardial infarction. (A) Immunofluorescent staining for von Willebrand (vWF) and a-smooth muscle actin (SMA) in left ventricle post-infarction. (B) Vascular density counts of vWF stained microvasculature in the left ventricle. (C) Vascular maturity estimated from vWF/SMA co-stained microvessels in the left ventricle; scale bar: 50 μm.

Microvascular neoangiogenesis at 8-week after myocardial infarction. (A) Immunofluorescent staining for von Willebrand (vWF) and a-smooth muscle actin (SMA) in left ventricle post-infarction. (B) Vascular density counts of vWF stained microvasculature in the left ventricle. (C) Vascular maturity estimated from vWF/SMA co-stained microvessels in the left ventricle; scale bar: 50 μm.

Discussion

Myocardial transplantation of human BM-MSCs has been widely reported to promote functional recovery following MI. Consistently, improved cardiac function was observed in our study, despite only a limited number of injected iPSC-MSCs remained in the transplanted mouse heart by 8-week after AMI. Similar observations were reported in myocardial transplantation of adult BM-MSCs [24]. Although it was reported that ESC-derived MSCs were more cardiomyogenic and angiogenic than BM-MSCs [25], there was no appreciable difference in infarct size and no distinct evidence to support cardiac or endothelial differentiation of the transplanted iMSCs in our study. Consistent with depressed radial strain in remote regions observed after anterior infarction [26], segmental short-axis analysis of the speckle tracking showed that ventricular radial strain at the lateral, inferior and posteroseptal walls were significantly compromised in the saline-injected, but not iMSC-injected, animals at 8-week after MI. Furthermore, strain analysed from the long-axis view, which was considered to be a better systolic contractility surrogate than LVEF [27,28], consistently showed enhanced strain in anterior wall that received iMSCs. This is consistent with observations in the POSEIDON trial, which showed regional contractility improvement in remote segments aside from MSC-injected segments in patients with advanced ventricular dysfunction [29]. The increased microvascular counts and enhanced vessel maturation in peri-infarct zones of iMSC-injected group suggested that paracrine-driven effect could have contributed partly to the positive outcome despite no appreciable iMSCs were found in the neighbouring ventricular segments. Nevertheless, the multi-segmental recovery in radial strain following iMSC injection into the anterior segment suggested that induced neoangiogenesis alone may not be responsible for the observed recovery in remote segments of the myocardium. Similar to previous reports by Berry et al. [17] and our group [30], reduction in wall stress and moderation of tissue stiffness in the infarcted anterior wall following cell transplantation may have resulted in overall geometry stabilization and functional preservation of other segments of the ventricular wall. This was further supported by the presence of telocytes in the interstitial space of infarcted anterior wall segment in iMSC-injected heart, which was consistent with their reported roles in co-ordinating and supporting architectural organization, tissue elasticity and mechanotransduction across network of myocardial segments [9,10,31]. Indeed, preservation of ventricular wall mechanics and structural organization for cyclical laminar shearing and extension experienced throughout systole and diastole are known to be critical in regional mechanical function of the heart [32]. Interestingly, the declining myocardial strain observed between 1-week and 8-week follow-up in the saline-injected group coincided with the period of reduced presence of cardiac telocytes following MI reported previously in left anterior descending (LAD) artery ligated rodent [33]. Consistently, presence of putative telocytes in the infarcted anterior segment that received iMSC transplantation, but not saline-injection, may be important in cardiac function improvement observed in our study. Consistent with beneficial effect of telocyte transplantation in recovering cardiac function [18], this was likely through sustaining the lattice of mechanical and biological interconnectivity from infarcted segment to other remote segments of the myocardium as demonstrated by close association of exogenous telocytes with resident telocytes observed in the infarcted and peri-infarcted zones. Analysis of the speckle strain from short-and long-axis views revealed that peri-infarct injection of iMSCs into the anterior wall benefited mostly radial strain (P < 0.05), but their effect was marginal in circumferential (P = 0.051) and limited in longitudinal (P = NS) strain. However, influence of iMSC injection angle (at 45° angle to the heart wall) in connection with outcome observed in radial strain cannot be totally discounted. Furthermore, it remains to be ascertained if torsional mechanics of the ventricular wall, which is known to intertwine with other segmental strain in affecting systolic deformation [34], had any role in the observed strain improvements in neighbouring and remote ventricular segments following iMSC injection. In summary, our results show that iPSC-derived hMSCs ameliorate MI-associated ventricular remodelling and preserve global myocardial strain via paracrine-driven effect by enhancing neoangiogenesis and promoting myocardial deformation/compliance via parenchymal and interstitial cell interactions in the infarcted myocardium.
  34 in total

1.  A new, simplified and accurate method for determining ejection fraction with two-dimensional echocardiography.

Authors:  M A Quinones; A D Waggoner; L A Reduto; J G Nelson; J B Young; W L Winters; L G Ribeiro; R R Miller
Journal:  Circulation       Date:  1981-10       Impact factor: 29.690

Review 2.  CD34+ stromal cells/fibroblasts/fibrocytes/telocytes as a tissue reserve and a principal source of mesenchymal cells. Location, morphology, function and role in pathology.

Authors:  L Díaz-Flores; R Gutiérrez; M P García; F J Sáez; L Díaz-Flores; F Valladares; J F Madrid
Journal:  Histol Histopathol       Date:  2014-02-03       Impact factor: 2.303

3.  Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance.

Authors:  Mark F Berry; Adam J Engler; Y Joseph Woo; Timothy J Pirolli; Lawrence T Bish; Vasant Jayasankar; Kevin J Morine; Timothy J Gardner; Dennis E Discher; H Lee Sweeney
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-02-10       Impact factor: 4.733

4.  A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improved myocardial remodeling.

Authors:  David Simpson; Hong Liu; Tai-Hwang Michael Fan; Robert Nerem; Samuel C Dudley
Journal:  Stem Cells       Date:  2007-05-24       Impact factor: 6.277

5.  Role of tissue structure on ventricular wall mechanics.

Authors:  Benjamin A Coppola; Jeffrey H Omens
Journal:  Mol Cell Biomech       Date:  2008-09

6.  Global longitudinal strain: a novel index of left ventricular systolic function.

Authors:  Shimon A Reisner; Peter Lysyansky; Yoram Agmon; Diab Mutlak; Jonathan Lessick; Zvi Friedman
Journal:  J Am Soc Echocardiogr       Date:  2004-06       Impact factor: 5.251

7.  Insights into the interstitium of ventricular myocardium: interstitial Cajal-like cells (ICLC).

Authors:  L M Popescu; Mihaela Gherghiceanu; M E Hinescu; D Cretoiu; Laura Ceafalan; T Regalia; A C Popescu; Carmen Ardeleanu; E Mandache
Journal:  J Cell Mol Med       Date:  2006 Apr-Jun       Impact factor: 5.310

Review 8.  Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking.

Authors:  Arco J Teske; Bart W L De Boeck; Paul G Melman; Gertjan T Sieswerda; Pieter A Doevendans; Maarten J M Cramer
Journal:  Cardiovasc Ultrasound       Date:  2007-08-30       Impact factor: 2.062

9.  Myocardial dysfunction in the periinfarct and remote regions following anterior infarction in rats quantified by 2D radial strain echocardiography: an observational cohort study.

Authors:  Raymond Q Migrino; Xiaoguang Zhu; Mineshkumar Morker; Tejas Brahmbhatt; Megan Bright; Ming Zhao
Journal:  Cardiovasc Ultrasound       Date:  2008-04-29       Impact factor: 2.062

10.  A distinct type of cell in myocardium: interstitial Cajal-like cells (ICLCs).

Authors:  S Kostin; L M Popescu
Journal:  J Cell Mol Med       Date:  2009-01-27       Impact factor: 5.310

View more
  13 in total

Review 1.  Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material.

Authors:  Vivek Tanavde; Candida Vaz; Mahendra S Rao; Mohan C Vemuri; Radhika R Pochampally
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

Review 2.  Pluripotent Stem Cells as a Robust Source of Mesenchymal Stem Cells.

Authors:  Carlos D Luzzani; Santiago G Miriuka
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

Review 3.  Pluripotent-derived Mesenchymal Stem/stromal Cells: an Overview of the Derivation Protocol Efficacies and the Differences Among the Derived Cells.

Authors:  Bruno Moisés de Matos; Anny Waloski Robert; Marco Augusto Stimamiglio; Alejandro Correa
Journal:  Stem Cell Rev Rep       Date:  2021-09-20       Impact factor: 5.739

4.  Microfluidic Single-Cell Analysis of Transplanted Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes After Acute Myocardial Infarction.

Authors:  Sang-Ging Ong; Bruno C Huber; Won Hee Lee; Kazuki Kodo; Antje D Ebert; Yu Ma; Patricia K Nguyen; Sebastian Diecke; Wen-Yi Chen; Joseph C Wu
Journal:  Circulation       Date:  2015-08-25       Impact factor: 29.690

5.  Mesenchymal Stem Cells and Mononuclear Cells From Cord Blood: Cotransplantation Provides a Better Effect in Treating Myocardial Infarction.

Authors:  Gecai Chen; Aihuan Yue; Hong Yu; Zhongbao Ruan; Yigang Yin; Ruzhu Wang; Yin Ren; Li Zhu
Journal:  Stem Cells Transl Med       Date:  2016-01-21       Impact factor: 6.940

6.  Repair of cartilage defects in osteoarthritis rats with induced pluripotent stem cell derived chondrocytes.

Authors:  Yanxia Zhu; Xiaomin Wu; Yuhong Liang; Hongsheng Gu; Kedong Song; Xuenong Zou; Guangqian Zhou
Journal:  BMC Biotechnol       Date:  2016-11-09       Impact factor: 2.563

Review 7.  Generation and Applications of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.

Authors:  Chengzhu Zhao; Makoto Ikeya
Journal:  Stem Cells Int       Date:  2018-07-31       Impact factor: 5.443

8.  Induced pluripotent stem cell-conditional medium inhibits H9C2 cardiomyocytes apoptosis via autophagy flux and Wnt/β-catenin pathway.

Authors:  Xiaoling Guo; Xiaohong Gu; Sohun Hareshwaree; Xing Rong; Lei Li; Maoping Chu
Journal:  J Cell Mol Med       Date:  2019-04-07       Impact factor: 5.310

Review 9.  Telocytes in regenerative medicine.

Authors:  Yihua Bei; Fei Wang; Changqing Yang; Junjie Xiao
Journal:  J Cell Mol Med       Date:  2015-06-08       Impact factor: 5.310

10.  iPSC-derived human cardiac progenitor cells improve ventricular remodelling via angiogenesis and interstitial networking of infarcted myocardium.

Authors:  K P Myu Mia Ja; Qingfeng Miao; Nicole Gui Zhen Tee; Sze Yun Lim; Manasi Nandihalli; Chrishan J A Ramachandra; Ashish Mehta; Winston Shim
Journal:  J Cell Mol Med       Date:  2015-11-27       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.